NASDAQ · MRNS
Marinus Pharmaceuticals, Inc.
$0.55$0.00 (0.0%)
Marinus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.76% below the high.
Loading market information…
NASDAQ · ANPC · USD
Stock price, earnings
Quote as of May 19, 2023, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
AnPac Bio-Medical Science Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 64.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow AnPac Bio-Medical Science Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
AnPac Bio-Medical Science Co., Ltd. is a biotechnology firm that specializes in developing and commercializing tests designed for the early detection and screening of various cancer types. These diagnostic tools leverage the company's unique Cancer Differentiation Analysis (CDA) technology and associated devices. AnPac Bio primarily provides these solutions to corporate entities and life insurance companies across the People's Republic of China. Additionally, the company extends its offerings to include comprehensive physical examination package services. AnPac Bio was established in 2010 and maintains its main operational base in Lishui, China.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.55$0.00 (0.0%)
Marinus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.76% below the high.
$1.00$0.00 (0.0%)
Angion Biomedica Corp.’s quoted price sits in the lower half of its reported 52-week range, 95.1% below the high.
$1.99+$0.10 (+5.29%)
Serina Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.2% below the high.
$0.33+$0.00 (+0.22%)
Allakos Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.9% below the high.
$6.49+$0.01 (+0.15%)
Freeline Therapeutics Holdings plc’s quoted price sits in the upper half of its reported 52-week range, 25.79% below the high.
$8.50+$0.01 (+0.12%)
Liminal BioSciences Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.63$0.00 (0.0%)
LakeShore Biopharma Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 92.71% below the high.
$1.35$0.00 (0.0%)
Gemini Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.53% below the high.
